Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun;27(6):1577–1587. doi: 10.3201/eid2706.204170

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.

PMC Copyright notice

Classification of cases of yellow fever vaccine–associated neurologic disease, São Paulo, Brazil, 2017–2018. Excluded cases, acute disseminated encephalomyelitis cases, and Guillain-Barré syndrome cases not shown. The area with n= 9 represents the intersection between the group "BC meningoencephalitis, YF-IgM+ (reactive CSF-YF-IgM)” and “CDC level 1, unclassified.” The area with n = 14 represents the intersection between the group "BC meningoencephalitis, YF-IgM– (nonconfirmed)" and "CDC level 1, unclassified." BC, Brighton Collaboration criteria; CDC, Centers for Disease Control and Prevention criteria; level 1 unclassified, level 1 neurologic disease not classifiable as level 2; level 2 neurotropic, level 2 neurotropic disease not further classified as suspected or definite neurotropic disease; other, includes atypical yellow fever vaccine–associated neurologic disease (optic neuritis, n = 1; ataxia, n = 1; opsoclonus-myoclonus-ataxia syndrome, n = 1); +, positive.